STOCKS TELEGRAPH

Tag: ZSAN stock

  • Zosano Pharma Corp. (ZSAN) stock Continues its Uptrend After Hours. Here’s why?

    On March 16, Zosano Pharma Corp. (ZSAN) rebounded during the regular session after a continuous downfall. The stock continued its uptrend in the after-hours as well. There is no official announcement or SEC filing from the company behind the stock’s comeback.

    During the regular session, the stock rallies by a huge 19.09% after fluctuating between $0.1551 and $0.1900. ZSAN closed the session at a price of $0.1840 per share while 15.48 million shares exchanged hands. The tock continued its uptrend into the following after-hours session to add a further 8.42%. Thus, ZSAN was trading at a value of $0.1995 per share at an after-hours volume of 1.64 million shares on Wednesday.

    The clinical-stage biopharmaceutical company, Zosano Pharma Corp. has a market capitalization of $26.49 million. Currently, the company has 171.46 million shares outstanding in the market.

    What is Happening with ZSAN?

    ZSAN stock had been in a downtrend for the past few days. After a persistent but mild downward spiral for a few days, the stock rebounded on Wednesday. Since there is no recent news or SEC filing, the stock seems to be moving due to external factors. It seems social media chatter, stock sentiment combined with the downtrend were the cause of the recovery. Investors seem to be buying the dip as it provided a good investment opportunity.

    ZSAN stock stands at a year-to-date loss of 60.85% while it lost 20.83% last month. Moreover, the stock subtracted a huge value of 87.48% in the past year.

    Upcoming Special Meeting

    Source: Corpbiz

    According to the SEC filing of February 25, the company will hold a special meeting of stockholders on April 8, 2022, at 8:30 am, ET. The purpose of the meeting is a Reverse Stock Split Proposal in the range of 1-for-5 to 1-for-50 for regaining compliance with Nasdaq’s minimum bid requirement.

    Furthermore, the meeting will take place virtually on the internet via a webcast.

    FDA’s Response Letter to ZSAN

    As per the company’s SEC filing of February 18, ZSAN received a response letter from FDA on February 17 regarding its NDA resubmission. The company had resubmitted its NDA for M207, zolmitriptan microneedle system on January 18. According to the letter, the resubmission failed to fulfill the previously identified deficiencies in the resubmission. Thus, FDA informed to not commence a substantive review of the application.

    Additionally, the company started to analyze and work over its best course of action regarding the NDA.

  • Zosano Pharma Corporation (ZSAN) stock plunged in the after-market. Here’s why

    Zosano Pharma Corporation (ZSAN) stock plunged in the after-market. Here’s why

    The stock of Zosano Pharma Corporation (ZSAN) ended the recent trading session at $0.16, gaining 31.62% from the previous session. During the last check, the stock of ZSAN lost 7.47% in the after-market, to $0.15. Recently, ZSAN’s petition for Zolmitriptan micro-needle was declined by the Food and Drug Administration. The company also filed the form DEF 14A with the SEC, on 25 February 2022.

    Zosano Pharma Corporation (ZSAN) is a clinical-stage pharmaceutical organization. ZSAN works around giving fundamental dispensing of medicine to patients utilizing its ransdermal micro-needle framework. Zosano accelerates drug integration into the blood circulatory system. The company has a market capitalization of $28.55 million, with 169.36 million of the pending shares. ZSAN has its base in Fremont, California, United States of America (USA).

    ZSAN’s News

    Recently, FDA declined the company’s petition for the Zolmitriptan microneedle system. A feedback report was disseminated to Zosano concerning the submission of 505(b)(2) medicine for M207. The reaction report expressed that the FDA didn’t ponder on the resubmitted application of M207. They will not start a meaningful audit of the application until they acquire a total reaction. Moreover, the company’s plan for laying out Zomig Nasal Spray 5 mg study was not satisfactory. ZSAN is assessing the subsequent stages. Notwithstanding, there can be no confirmations that the company will empower to keep chasing after FDA endorsement for M207.

    Moreover, on 8 February 2022, Zosano declared the pricing of its previous underwritten public offering. The offering included 51.2 million stocks, with one common share and one warrant, at a price of $0.30 for each stock. The warrants were exercisable immediately and had an expiry date of five years after the date of issue, with a price of $0.30 per stock. The aggregate profit for this offering was $15.4 million, prior to deducting guaranteeing limits and commissions.

    Further, the analysts at BTIG firm downgraded the stock rating of ZSAN from buy to neutral on 23 February 2022.

  • Zosano Pharma Corp. (ZSAN) stock Rolls Down After Hours on FDA Complete Response Letter

    On February 18, Zosano Pharma Corp. (ZSAN) filed a current report on Form 8-K with the SEC. According to the filing, the company has received a complete response letter regarding the recent resubmission of the New Drug Application for M207. Thus, the company’s resubmitted NDA was also deemed incomplete and unacceptable by the FDA. Consequently, the stock took a harsh hit in the after-hours on Friday.

    The stock was already trading in the red during the regular session at a volume of 9.24 million shares. ZSAN closed the session at $0.2159 with a loss of 3.49% after it reached a value of $0.2249. Following the SEC filing, the stock suffered a loss of 28.67% at 4.24 million shares. Hence, ZSAN stock was trading at a value of $0.1540 per share in the after-hours on Friday.

    The clinical-stage biopharmaceutical company, Zosano Pharma Corp. has a market capitalization of $37.02 million. Currently, the company has 171.46 million shares outstanding in the market.

    Recent Complete Response Letter

    Previously, the company had received a complete response letter from the FDA on October 19, 2020, regarding the NDA submission of M207. M207 is the companies investigational zolmitriptan transdermal microneedle system. The CRL highlighted the deficiencies in the NDA submission and suggested further studies and data provision. Therefore, the company conducted a Phase 1 PK study which was recently completed.

    On January 18, 2022, ZSAN resubmitted the 505(b)(2) New Drug Application for M207 with the FDA. As per February 18’s filing, the company received a response letter to the resubmission of February 17. According to the response letter, the company has failed to complete all the deficiencies highlighted in the previous CRL. So, the FDA will not be commencing a substantive review of the application unless a complete response is received.

    While the company is assessing its best course of action, there is no certainty as to whether it would be able to further pursue the NDA submission of M207. After the financial and strategic evaluation and planning, the company will decide upon a path.

    ZSAN’s Q3 Highlights

    In the third quarter of 2021, the company had a net loss of $8.7 million ($0.07/share), against $8.7 million ($0.11/share) in the year-ago quarter.

    ZSAN ended the quarter with cash and cash equivalents of $17.1 million on September 30, 2021. Comparatively, the company had $35.3 million on December 31, 2020.

  • Zosano Pharma Corp. (ZSAN) stock Nosedives After Hours on a Proposed Public Offering

    On February 08, Zosano Pharma Corp. (ZSAN) announced a proposed public offering of its common stock. As a result, the stock nosedived in the after-hours on Tuesday.

    The stock remained in the green during the regular trading session at a gain of 3.08%. ZSAN closed the session at $0.4726 with 3.5 million shares exchanging after reaching a high of $0.5025. Following the offering announcement, the stock took a hit to lose 36.10% at an after-hours volume of 2.8 million. Thus, ZSAN was trading at $0.3020, well below its 52-week low of $0.4100, in the after-hours on Tuesday.

    The clinical-stage biopharmaceutical company, Zosano Pharma Corp. is headquartered in Fremont, CA. Currently, its 118.35 million outstanding shares trade at a market capitalization of $54.26 million. ZSAN stock has added a mere 0.55% year to date while it suffered a huge blow of 76.25% last year.

    ZSAN: Proposed Public Offering

    On Tuesday, the company announced the initiation of an underwritten public offering. The offering will comprise of units having ZSAN’s common stock shares along with warrants to buy its common stock, sold by the company.

    Moreover, the sole book-running manager for the underwritten offering is Maxim Group LLC. Additionally, the actual size, terms, and completion of the offering were not disclosed in the press release. Hence, the company might be disclosing further details along with the pricing of the offering in a day or two.

    Publication of Clinical Data

    On January 05, the company announced the publication of its Phase 1 clinical trial data in the Journal of Vaccines and Immunology. The data was published in an article by the name “Immunogenicity and Safety of Inactivated Influenza Split-Virion Vaccine Administered via a Transdermal Microneedle System”.

    According to the data, a low dose of a trivalent influenza vaccine through a transdermal microneedle system produced proper antibody levels. These antibody levels met the three mentioned efficacy guidelines of EMEA for influenza vaccine. Furthermore, the vaccine dose through the system was also well tolerated.

    ZSAN: Board Changes

    On December 13, ZSAN announced some changes to its Board of Directors. Firstly, Elaine M. Yang was appointed to Board. Ms. Yang currently serves as the Chief Revenue Officer at Lyra Health Inc. Before this, she has also served at executive positions with Facebook as well as Genetech.

    In addition, effective December 31, 2021, Kleanthis Xanthopoulos was announced to step down from the Board.

  • ZosanoPharma Corporation (ZSAN) stock plunged in the premarket trading here’s why

    ZosanoPharma Corporation (ZSAN) stock plunged in the premarket trading here’s why

    In the premarket trading session, ZosanoPharma Corporation (ZSAN) shares had plunged at last check by -3.27% to trade at the price of $0.977. ZSAN stock had previously closed the session on Tuesday while gaining 3.02% to close at $1.01. In the past 50 days, the ZSAN stock average volume of trading has been 2.44 million which is greater than today’s volume traded of 1.28 million shares. In the past year up to date has ZSAN shares rising by 24.23% and in the past week the shares have moved up by 9.30%. In the past three and six months, the stock has shed-12.17% and added 66.45%.

    What you need to know about ZosanoPharma Corporation

    ZosanoPharma Corporation is a biotechnology company that is specifically a clinical stage biopharma as well. ZSAN stock focuses on the production and provision of unique and novel treatments as well as therapeutics to meet the unmet needs of clients that are both health-workers and patients. The company has a platform where it develops therapeutics to reduce migraine for suffering patients along with other bioactive molecules which can work through using a transdermal microneedle system. The company’s lead investigative product candidate is used for the acute treatment of migraines. It is known as Qtrypta (M207) which is a proprietary formulation of zolmitriptan. The company was established in 2006 and is based in Fremont, California.

    ZosanoPharma Corporation is a leading biopharma that is specializing in the discovery and production of migraine treatments. Recent studies made by the ZosanoPharma have shown the effect of the Qtrypta on migraine suffering by reducing its frequency and pain. This holds a positive result for the potential of Qtrypta to be used as a long-term treatment solution for migraines.

    Zosano has made progress on its lead candidate Qtrypta’s long term study data

    The data obtained for this clinical trial was long-term data which is said to be published in the Journal of Headache and Pain. The safety and efficacy testing level of the trial suggested that it was tolerated consistently and showed no adverse effects while being tested in the Phase 2/3 ZOTRIP study.

    The long-term data of the study showcased that the pain frequency of the migraine had reduced for the patients observed in the study. The migraine attacks occurred on average 2 times per month for the selected patients and after taking Qtrypta dosage they obtaining relief while facing no serious side effects. The migraine attacks only lasted 2 hours after the Qtryota dose was administered, this result showed an efficacy of 81% in migraine attacks. Furthermore, the freedom of pain was for 44% of the attacks and had also reduced the worst and troubling symptoms of migraine attack by 62% of attacks.

    The administration of the dosage was majorly cutaneous application site where reactions were formed however these reactions were 95% mildly rated with 80% of the incidents of reaction resolved within 48 hours of application. This recent development has caused ZSAN stock shares to rise as it will with further milestones hopefully achieved in the future.

  • Zosano Pharma Corp. (ZSAN) Stock Trending Undergoes Minor Volatility Despite Promising Debt Management

    Zosano Pharma Corp. (ZSAN) Stock Trending Undergoes Minor Volatility Despite Promising Debt Management

    Zosano Pharma Corp. (ZSAN) stock prices were down by 3.77% as of the market closing on June 15th, 2021, bringing the price per share down to USD$1.02 at the end of the trading day. After-hours trading saw the stock fall by another 5.54%, bringing it down to USD$0.96.

    Importance of Debt

    Debt is bad for bad companies; but for good companies, debt is a tool that they can use to help them grow. The underlying assumption is the ability to pay off lenders, without the company carries immense inherent risk. Without a guarantee of the fulfillment of their legal obligations, shareholders could lose the entirety of their investments. Even it doesn’t come to the worst-case scenario, the shoring up of balance sheets could result in a dilution of company shares with the issuance of offerings to raise capital. Ideally, a company takes on dilution in the hopes of using that capital to reinvest and usher in growth that exceeds that dilution, otherwise taking on debt could be a cheaper option.

    Solid Liquidity Position

    As of March 2021, ZSAN reported USD$1.63 million in debt, as compared to not having any debt as of the March of the prior year. This debt is offset by a solid liquidity position of USD$26.9 million, resulting in net cash reserves of USD$25.3 million.

    Debt Safety

    ZSAN’s most recent balance sheets show liabilities in the amount of USD$14.4 being due over the course of the following 12 months, with liabilities of USD$8.15 million due beyond that. In conjunction with cash reserves of USD$26.9 million, the company reported USD$243,000 worth of receivables due over the year. Resultingly, ZSAN boasts liquid assets that amount to USD$4.57 more than total liabilities.

    Course of Action

    This comfortable ratio indicates a relatively conservative balance sheet, with the elimination of debt not seeming too difficult. With the safety of its debt assured, owing to the surplus of cash over debt, the company’s future earnings will dictate what course their balance sheet takes moving forward. In the absence of significant operating revenue, investors rely on the hope of hasty commercialization of ZSAN’s new medical technology.

    Future Outlook for ZSAN

    Armed with a solid liquidity position and very manageable debt, ZSAN is poised to continue its trajectory of success. The company is keen to usher in further growth with the effective allocation of capital and debt. Current and potential investors are hopeful that management will continue to leverage the resources at their disposal to facilitate significant and sustained increases in shareholder value.

  • The Zosano Pharma Corp. (NASDAQ: ZSAN) stock rises by 12.78% in afterhours. Here’s to know why:

    The Zosano Pharma Corp. (NASDAQ: ZSAN) stock rises by 12.78% in afterhours. Here’s to know why:

    Zosano Pharma Corp. (NASDAQ: ZSAN) stock showed a downswing by 5.00% in the last trading close whereas the stock rises in after-hours by 12.78%. There is no recent news or press release available, to be the exact reason behind this change in ZSAN stock price. On 11 March, ZSAN has announced its fourth quarter and fiscal year 2020 financial results which could might be the reason behind this up and down in Zosano Pharma stock price. Zosano Pharma Corp is a biopharmaceutical company that focuses on developing products with rapid administration of approved molecules and established safety and efficacy profiles to provide benefit to the patient whereas in the market people do not get the treatment that they need.

    Financial Results

    • ZSAN has reported a net loss of $8.1 million in the fourth quarter of 2020 as compared to $8.9 million in the fourth quarter of 2019. For full-year 2020, ZSAN stock has experienced a net loss of $33.4 million compared to $37.6 million for the full year 2019.
    • ZSAN has calculated its Research and Development expenses as $5.4 million in the fourth quarter of 2020 compared with $5.6 million for the same quarter of 2019. The decrease of $0.2 was mainly due to $0.4 million of lower employee and consulting expenses. For full-year 2020, the R&D expenses were $21.6 million compared with $25.4 million in full-year 2019.
    • General and administrative expense in the fourth quarter of ZSAN financial year was $2.6 million, while for the fourth quarter of 2019 it was $3.1million. For the full year 2020, the G&A expense was $11.2 million while it was $11.8 million for the full year 2019. The decrease of $0.5 million and $0.6 million is due to lower employee-related expenses.
    • Lastly, ZSAN recorded its cash and cash equivalents as $35.3 million which was previously calculated as $6.3 million as of December 31, 2019.

    Conclusion

    If we look closely at the financial results, ZSAN has made better progress as compared to the previous year despite the pandemic situation going on in the world. This could be a solid reason for investors to show their interest in ZSAN stock that has caused the rise in stock. Furthermore, ZSAN has signed few important agreements, one of which is with Mitsubishi Tanabe Pharma Corporation and partnerships with EVERSANA which is a promising sign for the future of Zosano Pharma Corp.

  • 41 Stocks Making Sharp Moves in Pre Market Session

    41 Stocks Making Sharp Moves in Pre Market Session

    NanoVibronix Inc. (NASDAQ: NAOV) shares are trading down -4.55% at $1.05 at the time of writing after announcing $6.0 million private placement. Company’s 52-week ranged between $0.54 to $3.50.
    Merrimack Pharmaceuticals Inc. (MACK) stock plunged -6.93% to $6.04 in the pre-market trading. The most recent rating by JP Morgan, on October 07, 2016, is a Neutral.
    Curis Inc. (CRIS) is down more than -5.85% at $1.77 in pre-market hours Thursday December 03, 2020 after declaring that it will host Virtual Event to discuss CA-4948 clinical data. The stock had jumped over 22.88% to $1.88 in the last trading session.
    Before the trading started on December 03, 2020, Obalon Therapeutics Inc. (OBLN) is down -8.62% to reach $1.06. It has been trading in a 52-week range of $0.62 to $2.14.
    Artelo Biosciences Inc. (ARTL) grew over 7.53% at $0.7065 in pre-market trading today following announcement its appointment of drug discovery and development veteran Gregory R. Reyes, M.D., Ph.D. to the Company’s Board of Directors.
    Acorda Therapeutics Inc. (ACOR), a Biotechnology company, dropped about -3.54% at $0.79 in pre-market trading Thursday.
    Ampio Pharmaceuticals Inc. (AMPE) is up more than 6.8% at $1.1 in pre-market hours Thursday December 03, 2020 after declaring its phase I study for Inhaled Ampion advances to completing enrollment of COVID-19 patients with respiratory distress. The stock had jumped over 12.65% to $1.03 in the last trading session.
    Nxt-ID Inc. (NASDAQ: NXTD) shares are trading down -6.11% at $0.446 at the time of writing. Company’s 52-week ranged between $0.21 to $0.89.
    OrganiGram Holdings Inc. (OGI) stock moved down -2.86 percent to $1.36 in the pre-market trading. The company recently released fourth quarter 2020 results.
    InVivo Therapeutics Holdings Corp. (NVIV) gained over 14.27% at $0.7999 in pre-market trading Thursday December 03, 2020.
    HEXO Corp. (HEXO) lost over -5.98% at $1.1 in pre-market trading Thursday December 03, 2020 as the firm recently revealed that it has repositioned the UP Cannabis brand with a differentiator of 20% THC or higher in all dried flower products, every time.
    Before the trading started on December 03, 2020, Aurora Cannabis Inc. (ACB) is down -2.92% to reach $10.63. It has been trading in a 52-week range of $3.71 to $32.88.
    Before the trading started on December 03, 2020, Golar LNG Limited (GLNG) is down -6.67% to reach $8.75 after declaring that it intends to offer, issue and sell to the public 11,000,000 common shares, par value $1.00 per share, through an underwritten public offering. It has been trading in a 52-week range of $4.54 to $15.24.
    Aeterna Zentaris Inc. (AEZS) stock soared 3.1% to $0.455 in the pre-market trading. The most recent rating by Maxim Group, on July 19, 2017, is a Buy.
    Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) shares are trading up 9.23% at $4.26 at the time of writing after reporting that it has screened the first patients in a global trial of its oral insulin capsule ORMD-0801 for the treatment of Nonalcoholic steatohepatitis (NASH). Company’s 52-week ranged between $2.40 to $6.05. Analysts have a consensus price target of $5.50.
    Ashford Hospitality Trust Inc. (AHT), a REIT – Hotel & Motel company, rose about 7.36% at $2.48 in pre-market trading Thursday.
    Ideanomics Inc. (IDEX) grew over 0.86% at $2.35 in pre-market trading today. The technology firm lately declared that its subsidiary, Tree Technologies Sd. Bhd., which owns the Treeletrik brand, has hired Richard Teoh as its Chief Financial Officer.
    AIkido Pharma Inc. (AIKI) is down more than -2.2% at $0.59 in pre-market hours Thursday December 03, 2020. The stock had jumped over 8.94% to $0.60 in the last trading session.
    NIO Limited (NIO), a Auto Manufacturers company, dropped about -2.21% at $46.92 in pre-market trading Thursday after providing its November 2020 delivery results.
    Genius Brands International Inc. (GNUS) is up more than 2.14% at $1.43 in pre-market hours Thursday December 03, 2020. The stock had jumped over 5.26% to $1.40 in the last trading session.
    Micro Focus International plc (MFGP) gained over 2.81% at $5.12 in pre-market trading Thursday December 03, 2020 following the publication its findings of ‘Endless Modernization’ research with Standish Group.
    Trine Acquisition Corp. (NYSE: TRNE) shares are trading up 6.44% at $14.22 at the time of writing. Company’s 52-week ranged between $9.40 to $13.94.
    Before the trading started on December 03, 2020, Borr Drilling Limited (BORR) is down -6.29% to reach $0.7625. The firm recently declared unaudited results for the three and nine months ended September 30, 2020. It has been trading in a 52-week range of $0.24 to $9.12.
    Blink Charging Co. (BLNK), a Specialty Retail company, dropped about -2.83% at $22.35 in pre-market trading Thursday.
    Boxlight Corporation (BOXL) lost over -2.53% at $1.54 in pre-market trading Thursday December 03, 2020. An education technology firm recently reported that Shaun Marklew has been appointed as Chief Technology Officer and Patrick Foley will be appointed as Chief Financial Officer on January 16, 2021.
    Before the trading started on December 03, 2020, Pyxis Tankers Inc. (PXS) is up 10.87% to reach $1.02. It has been trading in a 52-week range of $0.62 to $1.37.
    Orbital Energy Group Inc. (OEG) is down more than -3.1% at $1.25 in pre-market hours Thursday December 03, 2020 following announcement its wholly-owned transmission & distribution division, Orbital Power Services signed a Master Services Agreement with a midwestern investor-owned utility.
    Telefonica S.A. (TEF) is down more than -2.64% at $4.43 in pre-market hours Thursday December 03, 2020. The stock had jumped over 1.56% to $4.55 in the last trading session.
    Longview Acquisition Corp. (NYSE: LGVW) shares are trading up 7.86% at $15.79 at the time of writing. Company’s 52-week ranged between $9.34 to $17.99.
    UP Fintech Holding Limited (NASDAQ: TIGR) shares are trading up 3.51% at $5.61 at the time of writing. Company’s 52-week ranged between $2.03 to $7.60.
    Veru Inc. (VERU) gained over 10.39% at $3.4 in pre-market trading Thursday December 03, 2020.
    Tonix Pharmaceuticals Holding Corp. (TNXP) grew over 2.46% at $0.6414 in pre-market trading today.
    Before the trading started on December 03, 2020, Orange S.A. (ORAN) is down -5.39% to reach $12.28 after reporting that it plans to launch a conditional voluntary public takeover bid on all the shares of Orange Belgium that it does not yet own. It has been trading in a 52-week range of $9.93 to $16.08.
    Switchback Energy Acquisition Corporation (SBE) gained over 2.27% at $30.17 in pre-market trading Thursday December 03, 2020.
    Nano Dimension Ltd. (NNDM), a Computer Hardware company, rose about 4.69% at $6.7 in pre-market trading Thursday after closing the previously reported registered direct offering of 11,960,160 of the Company’s American Depositary Shares at a price of $5.00 per ADS.
    Harmony Gold Mining Company Limited (HMY) is down more than -2.42% at $4.44 in pre-market hours Thursday December 03, 2020. The stock had dropped over 0.00% to $4.55 in the last trading session.
    Waddell & Reed Financial Inc. (WDR) stock moved up 46.33 percent to $24.89 in the pre-market trading after declaring a merger agreement with Macquarie Asset Management, under which Macquarie would acquire Waddell & Reed Financial, Inc. for $1.7 Billion.
    Limelight Networks Inc. (LLNW) stock plunged -2.78% to $4.2 in the pre-market trading. The most recent rating by Goldman, on November 30, 2020, is a Neutral.
    Before the trading started on December 03, 2020, XP Inc. (XP) is down -1.88% to reach $39.65 after announcing pricing of public follow-on offering. It has been trading in a 52-week range of $15.50 to $52.94.
    CBAK Energy Technology Inc. (NASDAQ: CBAT) shares are trading up 2.75% at $7.1 at the time of writing. Company’s 52-week ranged between $0.36 to $11.40.
    Splunk Inc. (SPLK) tumbled over -20.5% at $163.69 in pre-market trading today as the firm released fiscal third quarter 2021 financial results.

  • 35 stocks making the biggest moves premarket today

    35 stocks making the biggest moves premarket today

    FuelCell Energy Inc. (FCEL) stock soared 4.75% to $10.15 in the pre-market trading. The most recent rating by JP Morgan, on November 19, 2020, is a Neutral.

    SCWorx Corp. (NASDAQ: WORX) shares are trading down -6.76% at $2.07 at the time of writing. Company’s 52-week ranged between $1.00 to $14.88.

    Nano Dimension Ltd. (NNDM) lost over -12.1% at $5.74 in pre-market trading Monday, November 30, 2020, after announcing that it has entered into definitive agreements with investors for the sale of 11,960,160 of the Company’s American Depositary Shares (“ADSs”) at a price of $5.00 per ADS pursuant to a registered direct offering.

    Moderna Inc. (MRNA) is up more than 9.38% at $138.95 in pre-market hours on Monday, November 30, 2020 after the firm today announced that the primary efficacy analysis of the Phase 3 study of mRNA-1273 conducted on 196 cases confirms the high efficacy observed at the first interim analysis. The data analysis indicates a vaccine efficacy of 94.1%. The stock had jumped over 16.35% to $127.03 in the last trading session.

    FreightCar America Inc. (NASDAQ: RAIL) shares are trading down -3.99% at $2.65 at the time of writing. Company’s 52-week ranged between $0.73 to $2.87. Analysts have a consensus price target of $4.50.

    Blink Charging Co. (BLNK), a Specialty Retail company, dropped about -3.25% at $27.09 in pre-market trading Monday. The firm recently declared that it has acquired the EV charging operator U-Go Stations, Inc. and its portfolio of 44 DCFC charging locations.

    Zomedica Corp. (ZOM), a Drug Manufacturers – Specialty & Generic company, dropped about -1.12% at $0.1324 in pre-market trading Monday.

    GameStop Corp. (GME) is up more than 4.1% at $16.74 in pre-market hours Monday November 30, 2020 after declaring 2020 cyber week deals. The stock had jumped over 9.02% to $16.08 in the last trading session. GameStop Announces 2020 Cyber Week Deals.

    Riot Blockchain Inc. (RIOT) grew over 8.64% at $6.79 in pre-market trading today.

    Verastem Inc. (VSTM) stock moved up 5.03 percent to $2.09 in the pre-market trading after reporting the initiation of a Phase 2 registration-directed clinical trial of VS-6766, its RAF/MEK inhibitor, and defactinib, its FAK inhibitor, in patients with recurrent low-grade serous ovarian cancer (LGSOC).

    Tuniu Corporation (TOUR) gained over 6.58% at $3.4 in pre-market trading on Monday, November 30, 2020. Before the trading started on November 30, 2020.

    Novavax Inc. (NVAX) is down -8.31% to reach $115.25 after providing an update on its COVID-19 vaccine program. NVX‑CoV2373 is a stable, prefusion protein antigen derived from the genetic sequence of the SARS-CoV-2 coronavirus spike (S) protein and adjuvanted with Novavax’ proprietary Matrix‑M™. It has been trading in a 52-week range of $3.65 to $189.40.

    Occidental Petroleum Corporation (NYSE: OXY) shares are trading down -2.36% at $16.17 at the time of writing. Company’s 52-week ranged between $8.52 to $47.58. Analysts have a consensus price target of $18.

    RMG Acquisition Corp. (RMG) stock soared 6.6% to $18.1 in the pre-market trading. The firm recently revealed that the close of business on Tuesday, December 1, 2020, has been set as the record date for the determination of stockholders eligible to receive the proxy and vote at the special meeting to be held to consider and approve the previously announced merger with Romeo Systems, Inc., a Delaware corporation.

    Uxin Limited (UXIN) stock soared 2.53% to $1.62 in the pre-market trading. The most recent rating by JP Morgan, on October 23, 2019, is a Neutral.

    ReneSola Ltd (NYSE: SOL) shares are trading up 8.02% at $8.08 at the time of writing. The technology company recently announced the closing of the sale of a portfolio of operating projects located in the United Kingdom to Atmosclear Investments Ltd, an European renewable energy and cleantech private equity group. Company’s 52-week ranged between $0.85 to $5.67. Analysts have a consensus price target of $22.

    Kandi Technologies Group Inc. (KNDI) tumbled over -2.28% at $13.31 in pre-market trading today after CBAK Energy and Kandi Group signed a supply framework agreement.

    Vaxart Inc. (VXRT) is up more than 4.84% at $7.37 in pre-market hours on Monday, November 30, 2020. The stock had jumped over 9.84% to $7.03 in the last trading session. Before the trading started on November 30, 2020.

    Alibaba Group Holding Limited (BABA) is down -2.3% to reach $270.13. The internet retail company has been named a leader in Gartner’s 2020 Magic Quadrant for Cloud Database Management Systems. It has been trading in a 52-week range of $169.95 to $319.32.

    EyePoint Pharmaceuticals Inc. (EYPT) stock soared 1.97% to $0.55 in the pre-market trading. The most recent rating by B. Riley FBR, on April 06, 2020, is a Neutral.

    Canaan Inc. (NASDAQ: CAN) shares are trading down -7.83% at $5.3 at the time of writing after releasing its unaudited financial results for the three months ended September 30, 2020. Company’s 52-week ranged between $1.76 to $8.69.

    Heat Biologics Inc. (NASDAQ: HTBX) shares are trading down -0.88% at $1.13 at the time of writing. Company’s 52-week ranged between $0.19 to $4.30. Analysts have a consensus price target of $4.

    Yunji Inc. (YJ), an Internet Retail company, dropped about -7.35% at $3.53 in pre-market trading Monday. The firm recently declared its unaudited financial results for the third quarter ended September 30, 2020.

    India Globalization Capital Inc. (IGC) gained over 22.63% at $2.33 in pre-market trading Monday November 30, 2020.

    Oramed Pharmaceuticals Inc. (ORMP) stock moved up 38.65 percent to $6.17 in the pre-market trading. The healthcare firm recently reported that it has screened the first patients in its global Phase 3 trials of its oral insulin capsule ORMD-0801 for the treatment of type 2 diabetes (T2D). Before the trading started on November 30, 2020.

    Schlumberger Limited (SLB) is down -2.06% to reach $21.43. It has been trading in a 52-week range of $11.87 to $41.14.

    Ocugen Inc. (OCGN) stock plunged -1.71% to $0.294 in the pre-market trading. The firm recently revealed that Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder of Ocugen, will speak on “The Promise of Cell & Gene Therapies: Regulatory and Reimbursement Roadblocks” at Xconomy’s Xcelerating Life Sciences New York & Philadelphia Virtual Event on December 3 at 10:30 a.m. Before the trading started on November 30, 2020.

    Gold Fields Limited (GFI) is down -2.52% to reach $8.5. It has been trading in a 52-week range of $3.79 to $14.90. Before the trading started on November 30, 2020.

    Marathon Patent Group Inc. (MARA) is up 15.65% to reach $4.95. It has been trading in a 52-week range of $0.35 to $6.05.

    Kingsoft Cloud Holdings Limited (KC) stock soared 5.13% to $43.69 in the pre-market trading after reporting that it will be included in the MSCI China Index, effective after the U.S. market close on November 30, 2020. The most recent rating by Goldman, on June 29, 2020, is a Buy.

    NanoVibronix Inc. (NASDAQ: NAOV) shares are trading up 5.26% at $0.8 at the time of writing. Company’s 52-week ranged between $0.54 to $3.50.

    Waitr Holdings Inc. (WTRH) stock moved down -1.46 percent to $3.38 in the pre-market trading.

    Hennessy Capital Acquisition Corp. IV (HCAC) gained over 9.0% at $13.69 in pre-market trading on Monday, November 30, 2020.

    Trevena Inc. (TRVN) stock plunged -4.67% to $2.45 in the pre-market trading. The most recent rating by Guggenheim, on September 14, 2020, is a Buy.

    Suncor Energy Inc. (NYSE: SU) shares are trading down -0.58% at $17.15 at the time of writing. The firm lately publicized that it, together with the other Syncrude joint venture owners – Imperial Oil Resources Limited, CNOOC Oil Sands Canada, and Sinopec Oil Sands Partnership – have agreed in principle for Suncor to become the operator of the Syncrude project by the end of 2021. Company’s 52-week ranged between $9.60 to $34.56.

  • Pre-Market Cues: 45 Stocks Roaring for Change On November 16th

    Pre-Market Cues: 45 Stocks Roaring for Change On November 16th

    CBAK Energy Technology Inc. (CBAT) stock soared 51.22% to $9.3 in pre-market trading.
    Asia Pacific Wire & Cable Corporation Limited (NASDAQ: APWC) shares are trading up 9.74% at $2.14 at the time of writing. The company’s 52-week range was noted as $0.89 to $2.69.
    Electra Meccanica Vehicles Corp. (SOLO) grew over 8.9% at $6.85 in pre-market trading today following analyst’s prediction that electric vehicles will overtake the global automotive sector in the near future.
    CPS Technologies Corporation (CPSH), an Electronic Components company, dropped about -8.72% at $1.57 in pre-market trading Monday.
    HighPoint Resources Corporation (HPR) stock moved up 77.39 percent to $6.67 in the pre-market trading after the news that Bonanza Creek Energy, Inc. BCEI and HighPoint Resources Corporation HPR have agreed on a merger worth $376 million.
    Navidea Biopharmaceuticals Inc. (NAVB) lost over -5.8% at $2.6 in pre-market trading Monday 16 November 2020 after the company announced its financial results for the third quarter and year-to-date 2020.
    Hall of Fame Resort & Entertainment Company (HOFV) is down more than -11.65% at $2.2 in pre-market hours Monday 16 November 2020 as the company and the NFL alumni association offered updates on the success of the inaugural NFL alumni academy. The stock had jumped over 22.06% to $2.49 in the last trading session.
    Before the trading started on 16 November 2020, GreenPower Motor Company Inc. (GP) is up 6.98% to reach $13.48 after the company posted its 2nd quarter financial results for 2021. It has been trading in a 52-week range of $0.82 to $23.45.
    Zomedica Pharmaceuticals Corp. (ZOM) stock plunged -7.07% to $0.088 in the pre-market trading as the plans to initiate commercialization on 30 March 2021 of its TRUFORMATM point-of-care diagnostic platform revealed.
    Polar Power Inc. (NASDAQ: POLA) shares are trading up 7.81% at $3.59 at the time of writing. Company’s 52-week range was noted as $0.95 to $6.56.
    Sino-Global Shipping America Ltd. (SINO) tumbled over -2.92% at $2.66 in pre-market trading today.
    Pinduoduo Inc. (PDD), an Internet Retail company, dropped about -1.78% at $148.59 in pre-market trading Monday as the firm unveils its Q3 results.
    Tellurian Inc. (TELL) stock moved down -4.51 percent to $0.9644 in the pre-market trading as the news appeared that the company is pondering new Asia gas deals After Petronet snub.
    9 Meters Biopharma Inc. (NMTR) lost over -3.58% at $0.8 in pre-market trading Monday 16 November 2020 as the company revealed financial results and business updates.
    Centennial Resource Development Inc. (CDEV) is down more than -2.88% at $0.741 in pre-market hours Monday 16 November 2020 after the company said Sean R. Smith, Chief Executive Officer, is set to attend the Bank of America Securities Global Energy Conference to be held virtually on Thursday. The stock had jumped over 9.14% to $0.76 in the last trading session.
    Before the trading started on 16 November 2020, Genius Brands International Inc. (GNUS) is up 7.38% to reach $1.31, after the company stated that it is set to host a conference call at 10:00 a.m. Eastern Time on Monday, November 16, 2020, to review major initiatives underway and recent developments. The stock has been trading in a 52-week range of $0.05 to $11.73.
    CureVac N.V. (CVAC) stock soared 8.38% to $81.5 in the pre-market trading after the report that the covid-19 vaccine could be a drug industry game-changer. The most recent rating by Jefferies, on September 08, 2020, is a Hold.
    Apple Hospitality REIT Inc. (NYSE: APLE) shares are trading down -2.83% at $12.02 at the time of writing after the company posted 3rd quarter results of operation. The company’s 52-week range was noted as $4.48 to $16.42. Analysts have a consensus price target of $13.
    Transocean Ltd. (RIG) tumbled over -3.7% at $1.04 in pre-market trading today as the company stock soared 53% since the earnings announcement.
    Cinedigm Corp. (CIDM), an Entertainment company, rose about 8.33% at $0.65 in pre-market trading Monday as the company has purchased North American distribution rights to 100 DAYS TO LIVE, a taut psychological thriller set in the world of suicide prevention and mental health.
    Range Resources Corporation (RRC) stock moved down -5.57 percent to $6.78 in pre-market trading as the company recently revealed disappointing earnings.
    UP Fintech Holding Limited (TIGR) gained over 11.9% at $6.02 in pre-market trading Monday 16 November 2020 as the capital market giant revealed that it will announce its Q3 results on November 23, 2020.
    Taubman Centers Inc. (TCO) is up more than 8.11% at $42.68 in pre-market hours Monday 16 November 2020 after the publication report that Simon Property and Taubman have finally agreed on a merger on a well-reduced price of $43.00 per share in cash. The stock had jumped over 5.53% to $39.48 in the last trading session.
    Before the trading started on 16 November 2020, Banco Bilbao Vizcaya Argentaria S.A. (BBVA) is up 15.24% to reach $4.31 after the announcement that PNC Financial Services Group Inc (NYSE: PNC) is set to take over Banco Bilbao Vizcaya Argentaria (BBVA) U.S. business in an $11 billion all-cash deal. The stock has been trading in a 52-week range of $2.49 to $5.80.
    Kandi Technologies Group Inc. (KNDI) stock soared 7.62% to $7.77 in the pre-market trading as the Company announced that It completed a registered direct offering of 9,404,392 shares of its securities at a sales price of $6.38 per share, raising about $60,000,000 in net gross proceeds to the Firm before deducting the selling agent’s fees and other expected offering expenditures incurred by the Company.
    Textainer Group Holdings Limited (NYSE: TGH) shares are trading down -5.5% at $15.65 at the time of writing after the company posted its third-quarter results. The company’s 52-week range was noted as $5.50 to $17.33. Analysts have a consensus price target of $18.
    Gulfport Energy Corporation (GPOR) tumbled over -45.61% at $0.13 in pre-market trading today after the company filed for bankruptcy.
    Akerman Corp. (KERN), a Health Information Services company, dropped about -3.46% at $2.79 in pre-market trading Monday after the company posted its earnings results.
    United States Antimony Corporation (UAMY) stock moved up 4.17 percent to $0.375 in the pre-market trading.
    ADiTx Therapeutics Inc. (ADTX) lost over -2.03% at $1.93 in pre-market trading Monday 16 November 2020 as the company offered the latest business updated as well as its fiscal quarterly report.
    Arbutus Biopharma Corporation (ABUS) is up more than 10.19% at $4.0 in pre-market hours Monday 16 November 2020 after the firm revealed presentation of phase 1a/1b clinical trial results for AB-729 in chronic hepatitis B subjects at the liver meeting digital experience, the American Association for the study of Liver Diseases meeting. The stock had jumped over 2.25% to $3.63 in the last trading session.
    Before the trading started on 16 November 2020, Ideanomics Inc. (IDEX) is up 31.31% to reach $1.3 after the company revealed the final agreement to take over Timios holding corps. It has been trading in a 52-week range of $0.28 to $3.98.
    Pacific Ethanol Inc. (PEIX) stock soared 4.71% to $6.0 in the pre-market trading as the company announced Q3 results. The most recent rating by BWS Financial, on September 22, 2020, is a Buy.
    CEL-SCI Corporation (AMEX: CVM) shares are trading up 10.5% at $14.0 at the time of writing. The company’s 52-week range was noted as $6.35 to $18.00. Analysts have a consensus price target of $18.
    AMC Entertainment Holdings Inc. (AMC) grew over 8.42% at $3.22 in pre-market trading today following news that Cinemark joins AMC in pursuing a shortened movie window.
    Sogou Inc. (SOGO), an Internet Content & Information company, dropped about -3.14% at $8.64 in pre-market trading Monday as the company unveiled its Q3, 2020 results.
    ObsEva SA (OBSV) stock moved up 18.84 percent to $2.46 in the pre-market trading as the company announced the positive topline results of PROLONG, the Phase 2a proof-of-concept, randomized, double-blind, placebo-controlled trial of laropiprant in preterm labor.
    Denison Mines Corp. (DNN) lost over -9.3% at $0.32 in pre-market trading Monday 16 November 2020 after the company announced the establishment of the At-The-Market Program.
    Pyxis Tankers Inc. (PXS) is down more than -25.74% at $0.8763 in pre-market hours Monday 16 November 2020 as the company announced results for its 3rd quarter and year to date. The stock had dropped over 0.00% to $1.18 in the last trading session.
    Before the trading started on 16 November 2020, Qutoutiao Inc. (QTT) is down -2.13% to reach $2.3. It has been trading in a 52-week range of $2.12 to $6.55.
    Uxin Limited (UXIN) stock plunged -3.85% to $1.0 in the pre-market trading after the news that the company’s Net Promoter Score (NPS) increases to 30 during the quarter ended September 30, 2020. The most recent rating by JP Morgan, on October 23, 2019, is at a Neutral.
    VistaGen Therapeutics Inc. (NASDAQ: VTGN) shares are trading down -2.13% at $0.6851 at the time of writing. The company’s 52-week range was noted as $0.29 to $1.15. Analysts have a consensus price target of $6.
    Sypris Solutions Inc. (SYPR), an Auto Parts company, dropped about -3.6% at $1.34 in pre-market trading Monday after the company announced its 3rd quarter earnings results.
    Alterity Therapeutics Limited (ATHE) stock moved up 169.57 percent to $3.1 in the pre-market trading.